The USC Norris Comprehensive Cancer Center (NCCC) will continue in its mission to support basic research on the molecular genetic mechanisms underlying cancer, and translational research aimed at using discoveries in basic science to improve patient care. Now in its 17'*^ year of operation, the Transgenic/Knockout Mouse Core continues to offer a full range of mouse genome manipulation services. These include the targeting of genes in ES cells, the generation of gene targeted mice by injection of ES cells into blastocysts, and the production of transgenic mice by pronuclear injection. In addition to these major services, the Core also offers a number of ancillary services, including cryopreservation of embryos, rederivation of mouse strains, and in vitro fertilization. Finally, in the long term, the Core proposes to offer ES cell injection and gene knockouts in rats. In addition to funding from the Cancer Center Core Grant, the Core receives a large contribution from the Keck School of Medicine ($150,000 in FY 09-10, projected to continue yearly).The Core also receives support from the Zilkha Neurogenetics Institute ($25,000) and the College of Letters, Arts, and Sciences ($10,000). This broad support from several USC schools/Institutes leverages the CCCG contribution, enabling the Core to continue to offer a wide range of services at competitive prices to Cancer Center investigators. The Core is directed by Robert Maxson, Ph.D. Professor of Biochemistry and Molecular Biology (5% FTE). It is staffed by Dr. Nancy Wu (90%), an expert mouse embryologist and injectionist with 17 years of experience;and Dr. Mandy Ting (50%), an expert in ES cell manipulation. Assisting with all of Core functions is Youzhen Yan (90%) and John Johnson (10%). Core policies, including pricing, are set by a User's Committee in consultation with the Cancer Center Executive Committee. Outside prices are established by cost analysis. Prices for in house investigators are reduced from outside prices, depending on the academic affiliation of the investigator and the extent to which the investigator's unit supports the Core. Prices are listed online on the Core's website in the NCCC Shared Resources webpage. Also on the Core's website are order forms for Core services. The Core at its current staffing of 2.45 FTEs has the ability to perform four to six pronuclear injections, one gene targeting in ES cells, and one to two injections of ES cells into blastocysts to produce targeted mice.

Public Health Relevance

Access for NCCC investigators to state-of-the-art transgenic and knockout mouse technology is fundamental to the dual goals of supporting basic research on the molecular genetic mechanisms underlying cancer and translational research aimed at using discoveries in basic science to improve patient care. This technology is a virtual requirement for understanding the roles of specific genes in oncogenic processes, and is also increasingly important in translational studies on potential new therapies.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA014089-39
Application #
8589366
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-12-01
Budget End
2014-11-30
Support Year
39
Fiscal Year
2014
Total Cost
$117,937
Indirect Cost
$42,915
Name
University of Southern California
Department
Type
DUNS #
072933393
City
Los Angeles
State
CA
Country
United States
Zip Code
90089
Schaal, Justin B; Maretzky, Thorsten; Tran, Dat Q et al. (2018) Macrocyclic ?-defensins suppress tumor necrosis factor-? (TNF-?) shedding by inhibition of TNF-?-converting enzyme. J Biol Chem 293:2725-2734
Iriondo, Oihana; Liu, Yarong; Lee, Grace et al. (2018) TAK1 mediates microenvironment-triggered autocrine signals and promotes triple-negative breast cancer lung metastasis. Nat Commun 9:1994
Robison, Nathan J; Yeo, Kee Kiat; Berliner, Adrian P et al. (2018) Phase I trial of dasatinib, lenalidomide, and temozolomide in children with relapsed or refractory central nervous system tumors. J Neurooncol 138:199-207
Naseem, Madiha; Barzi, Afsaneh; Brezden-Masley, Christine et al. (2018) Outlooks on Epstein-Barr virus associated gastric cancer. Cancer Treat Rev 66:15-22
Peres, Lauren C; Risch, Harvey; Terry, Kathryn L et al. (2018) Racial/ethnic differences in the epidemiology of ovarian cancer: a pooled analysis of 12 case-control studies. Int J Epidemiol 47:460-472
Sebio, A; Stintzing, S; Heinemann, V et al. (2018) A genetic variant in Rassf1a predicts outcome in mCRC patients treated with cetuximab plus chemotherapy: results from FIRE-3 and JACCRO 05 and 06 trials. Pharmacogenomics J 18:43-48
Guo, Hao; Lee, Changrim; Shah, Mihir et al. (2018) A novel elastin-like polypeptide drug carrier for cyclosporine A improves tear flow in a mouse model of Sjögren's syndrome. J Control Release 292:183-195
Peddi, Santosh; Pan, Xiaoli; MacKay, John Andrew (2018) Intracellular Delivery of Rapamycin From FKBP Elastin-Like Polypeptides Is Consistent With Macropinocytosis. Front Pharmacol 9:1184
Kahn, Michael (2018) Wnt Signaling in Stem Cells and Cancer Stem Cells: A Tale of Two Coactivators. Prog Mol Biol Transl Sci 153:209-244
Zhao, Yi; Wu, Kaijin; Wu, Yongfeng et al. (2018) Characterization of Imatinib Resistant CML Leukemic Stem/Initiating Cells and Their Sensitivity to CBP/Catenin Antagonists. Curr Mol Pharmacol 11:113-121

Showing the most recent 10 out of 842 publications